satoreotide trizoxetan
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroenteropancreatic Neuroendocrine Tumors
Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Trial Timeline
Jun 1, 2014 → Jun 1, 2015
NCT ID
NCT02162446About satoreotide trizoxetan
satoreotide trizoxetan is a phase 1/2 stage product being developed by Ipsen for Gastroenteropancreatic Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02162446. Target conditions include Gastroenteropancreatic Neuroendocrine Tumors.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03697551 | Phase 2 | Terminated |
| NCT02162446 | Phase 1/2 | Completed |
Competing Products
9 competing products in Gastroenteropancreatic Neuroendocrine Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 41 |
| Lutathera + Gallium 68 Dotatate | Novartis | Phase 1 | 33 |
| Lutathera® | Novartis | Pre-clinical | 23 |
| Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus | Novartis | Phase 1 | 33 |
| Lanreotide Autogel 120 mg + Temozolomide (TMZ) | Ipsen | Phase 2 | 49 |
| Lanreotide autogel | Ipsen | Phase 3 | 74 |